Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009